A pyrosequencing-based approach to high-throughput identification of influenza A(H3N2) virus clades harboring antigenic drift variants

Journal of Clinical Microbiology

Volumn 55, Issue 1, 2017, Pages 145-154

  Mishin, Vasiliy P ^a   Baranovich, Tatiana ^a,b   Garten, Rebecca ^a   Chesnokov, Anton ^a,c   Abd Elal, Anwar I ^a,c   Adamczyk, Michelle ^a,c   LaPlante, Jennifer ^d   St George, Kirsten ^d   Fry, Alicia M ^a   Barnes, John ^a   Chester, Stephanie C ^e   Xu, Xiyan ^a   Katz, Jacqueline M ^a   Wentworth, David E ^a   Gubareva, Larisa V ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b Carter Consulting Inc   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

^d WADSWORTH CENTER   (United States)

^e ASSOCIATION OF PUBLIC HEALTH LABORATORIES   (United States)

Author keywords

A(H3N2); Genotyping; Influenza; Pyrosequencing

Indexed keywords

VIRUS RNA; INFLUENZA VIRUS HEMAGGLUTININ;

ANTIGENIC DRIFT; ANTIGENIC VARIATION; ARTICLE; BIOINFORMATICS; CLADISTICS; CONTROLLED STUDY; HIGH THROUGHPUT SEQUENCING; IMMUNOGENETICS; INFLUENZA A VIRUS (H3N2); MUTATIONAL ANALYSIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PYROSEQUENCING; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS IDENTIFICATION; VIRUS ISOLATION; CLASSIFICATION; EVALUATION STUDY; GENETIC DRIFT; GENETICS; GENOTYPING TECHNIQUE; HUMAN; INFLUENZA; ISOLATION AND PURIFICATION; PROCEDURES; SENSITIVITY AND SPECIFICITY; VIROLOGY;

GENETIC DRIFT; GENOTYPING TECHNIQUES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; POLYMORPHISM, SINGLE NUCLEOTIDE; SENSITIVITY AND SPECIFICITY;

EID: 85008395361     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01840-16     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention (CDC). 2013. Influenza activity - United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morb Mortal Wkly Rep 62:473-479.
2. Appiah GD, Blanton L, D'Mello T, Kniss K, Smith S, Mustaquim D, Steffens C, Dhara R, Cohen J, Chaves SS, Bresee J, Wallis T, Xu X, Abd Elal AI, Gubareva L, Wentworth DE, Katz J, Jernigan D, Brammer L, Centers for Disease Control and Prevention (CDC). 2015. Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep 64:583-590.
3. Kawaoka Y, Krauss S, Webster RG. 1989. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 63:4603-4608.
4. Doshi P. 2008. Trends in recorded influenza mortality: United States, 1900-2004. Am J Public Health 98:939-945. https://doi.org/10.2105/AJPH.2007.119933.
5. Wilson IA, Cox NJ. 1990. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 8:737-771. https://doi.org/10.1146/annurev.iy.08.040190.003513.
6. Gamblin SJ, Skehel JJ. 2010. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403-28409. https://doi.org/10.1074/jbc.R110.129809.
7. Bedford T, Suchard MA, Lemey P, Dudas G, Gregory V, Hay AJ, McCauley JW, Russell CA, Smith DJ, Rambaut A. 2014. Integrating influenza antigenic dynamics with molecular evolution. eLife 3:e01914. https://doi.org/10.7554/eLife.01914.
8. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305:371-376. https://doi.org/10.1126/science.1097211.
9. Ito T, Suzuki Y, Mitnaul L, Vines A, Kida H, Kawaoka Y. 1997. Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology 227:493-499. https://doi.org/10.1006/viro.1996.8323.
10. Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, Christodoulou E, Walker PA, Liu J, Skehel JJ, Gamblin SJ, Hay AJ, Daniels RS, McCauley JW. 2012. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A 109: 21474-21479. https://doi.org/10.1073/pnas.1218841110.
11. Mohr PG, Deng YM, McKimm-Breschkin JL. 2015. The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virol J 12:67. https://doi.org/10.1186/s12985-015-0295-3.
12. Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. 2012. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic acid receptors. J Virol 86:13371-13383. https://doi.org/10.1128/JVI.01426-12.
13. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, Lackenby A, Daniels R, Hay A. 2010. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol 84: 6769-6781. https://doi.org/10.1128/JVI.00458-10.
14. World Health Organization (WHO) Influenza Centre, London. 2012. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere 2013. WHO Influenza Centre, London, United Kingdom. https://www.crick.ac.uk/media/221897/interim-report-september-2012-2.pdf.
15. Barr IG, Russell C, Besselaar TG, Cox NJ, Daniels RS, Donis R, Engelhardt OG, Grohmann G, Itamura S, Kelso A, McCauley J, Odagiri T, Schultz-Cherry S, Shu Y, Smith D, Tashiro M, Wang D, Webby R, Xu X, Ye Z, Zhang W, Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013-2014. 2014. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 32:4713-4725. https://doi.org/10.1016/j.vaccine.2014.02.014.
16. World Health Organization (WHO). 2013. Influenza A(H3N2) candidate vaccine viruses and potency testing reagents for vaccine development and production for the northern hemisphere 2013-14. http://www.who.int/influenza/vaccines/virus/candidates-reagents/summary-a-h3n2-cvv-nh1314.pdf?ua-1.
17. World Health Organization (WHO). 2014. Influenza A(H3N2) candidate vaccine viruses and potency testing reagents for development and production of vaccines for use in the northern hemisphere 2014-2015 influenza season. http://www.who.int/influenza/vaccines/virus/candidates-reagents/summary-a-h3n2-cvv-nh1415.pdf?ua-1. Accessed 6 June 6 2016.
18. Pebody RG, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, Green HK, Cottrell S, Johnston J, de Lusignan S, Moore C, Gunson R, Robertson C, McMenamin J, Zambon M. 2015. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill 20:pii-21025. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-21025.
19. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, Fonseca K, Charest H, Gubbay JB, Petric M, Krajden M, Kwindt TL, Martineau C, Eshaghi A, Bastien N, Li Y. 2015. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill 20:pii-21022. http://www.eurosurveillance.org/Viewarticle.aspx?ArticleId-21022.
20. Broberg E, Snacken R, Adlhoch C, Beaute J, Galinska M, Pereyaslov D, Brown C, Penttinen P, on behalf of the WHO European Region and the European Influenza Surveillance Network. 2015. Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype. Euro Surveill 20:pii-21023. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-21023.
21. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. 2015. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep 12:1-6. https://doi.org/10.1016/j.celrep.2015.06.005.
22. Elahi E, Ronaghi M. 2004. Pyrosequencing: a tool for DNA sequencing analysis. Methods Mol Biol 255:211-219. https://doi.org/10.1385/1-59259-752-1:211.
23. Novais RC, Thorstenson YR. 2011. The evolution of pyrosequencing for microbiology: from genes to genomes. J Microbiol Methods 86:1-7. https://doi.org/10.1016/j.mimet.2011.04.006.
24. Harrington CT, Lin EI, Olson MT, Eshleman JR. 2013. Fundamentals of pyrosequencing. Arch Pathol Lab Med 137:1296-1303. https://doi.org/10.5858/arpa.2012-0463-RA.
25. Deyde VM, Sampath R, Gubareva LV. 2011. RT-PCR/electrospray ionization mass spectrometry approach in detection and characterization of influenza viruses. Expert Rev Mol Diagn 11:41-52. https://doi.org/10.1586/erm.10.107.
26. Levine M, Sheu TG, Gubareva LV, Mishin VP. 2011. Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing. J Clin Microbiol 49:1307-1312. https://doi.org/10.1128/JCM.02424-10.
27. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV. 2010. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 54:1102-1110. https://doi.org/10.1128/AAC.01417-09.
28. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. 2010. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res 85:354-360. https://doi.org/10.1016/j.antiviral.2009.10.022.
29. Tamura D, Okomo-Adhiambo M, Mishin VP, Guo Z, Xu X, Villanueva J, Fry AM, Stevens J, Gubareva LV. 2015. Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitorresistant influenza A(H3N2) viruses. Antimicrob Agents Chemother 59: 2374-2379. https://doi.org/10.1128/AAC.04939-14.
30. Deng YM, Caldwell N, Barr IG. 2011. Rapid detection and subtyping of human influenza A viruses and reassortants by pyrosequencing. PLoS One 6:e23400. https://doi.org/10.1371/journal.pone.0023400.
31. Chambers C, Skowronski DM, Sabaiduc S, Murti M, Gustafson R, Pollock S, Hoyano D, Allison S, Krajden M. 2015. Detection of influenza A(H3N2) clade 3C.2a viruses in patients with suspected mumps in British Columbia, Canada, during the 2014/15 influenza season. Euro Surveill 20:pii-30015. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-21239.
32. Bissielo A, Pierse N, Huang QS, Thompson MG, Kelly H, Mishin VP, Turner N, Shivers. 2016. Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: interim estimates. Euro Surveill 21:pii-30101. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-21342.
33. Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM. 2016. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J Infect Dis 214:1010-1019. https://doi.org/10.1093/infdis/jiw181.
34. World Health Organization (WHO) Global Influenza Surveillance Network. 2011. Manual for the laboratory diagnosis and virological surveillance of influenza. http://whqlibdoc.who.int/publications/2011/9789241548090-eng.pdf.
35. Centers for Disease Control (CDC). 2008. 510(k) Summary for Centers for Disease Control and Prevention human influenza virus real-time RT-PCR detection and characterization panel. http://www.accessdata.fda.gov/cdrh-docs/pdf8/k080570.pdf.
36. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. 2010. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54:2517-2524. https://doi.org/10.1128/AAC.01739-09.
37. Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, Wentworth DE. 2009. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza A viruses. J Virol 83:10309-10313. https://doi.org/10.1128/JVI.01109-09.
38. Hall TA. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41:95-98.
39. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739. https://doi.org/10.1093/molbev/msr121.
40. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389-3402. https://doi.org/10.1093/nar/25.17.3389.